Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

Coherus BioSciences, Inc. (CHRS): $4.12

0.07 (+1.73%)

POWR Rating

Component Grades

Momentum

B

Stability

F

Sentiment

Quality

C

Add CHRS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#146 of 380

in industry

CHRS Price/Volume Stats

Current price $4.12 52-week high $14.11
Prev. close $4.05 52-week low $3.60
Day low $4.06 Volume 617,982
Day high $4.27 Avg. volume 1,501,124
50-day MA $6.44 Dividend yield N/A
200-day MA $7.94 Market Cap 331.88M

CHRS Stock Price Chart Interactive Chart >

CHRS POWR Grades

  • Momentum is the dimension where CHRS ranks best; there it ranks ahead of 78.35% of US stocks.
  • The strongest trend for CHRS is in Growth, which has been heading up over the past 179 days.
  • CHRS ranks lowest in Stability; there it ranks in the 3rd percentile.

CHRS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CHRS is -0.93 -- better than just 5.42% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -4.36 for COHERUS BIOSCIENCES INC; that's greater than it is for merely 3.57% of US stocks.
  • Revenue growth over the past 12 months for COHERUS BIOSCIENCES INC comes in at -39.61%, a number that bests only 6.24% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to COHERUS BIOSCIENCES INC are AXDX, ASTC, LQDA, TARS, and TTOO.
  • Visit CHRS's SEC page to see the company's official filings. To visit the company's web site, go to www.coherus.com.

CHRS Valuation Summary

  • In comparison to the median Healthcare stock, CHRS's price/sales ratio is 60.78% lower, now standing at 2.
  • CHRS's price/sales ratio has moved down 13.6 over the prior 104 months.

Below are key valuation metrics over time for CHRS.

Stock Date P/S P/B P/E EV/EBIT
CHRS 2023-05-23 2.0 -1.9 -1.4 -3.5
CHRS 2023-05-22 2.0 -1.8 -1.3 -3.4
CHRS 2023-05-19 2.0 -1.9 -1.3 -3.5
CHRS 2023-05-18 2.0 -1.8 -1.3 -3.5
CHRS 2023-05-17 2.2 -2.1 -1.5 -3.6
CHRS 2023-05-16 2.3 -2.1 -1.5 -3.7

CHRS Growth Metrics

    The year over year revenue growth rate now stands at -31.41%.
  • Its year over year net income to common stockholders growth rate is now at -175.63%.
  • The 2 year cash and equivalents growth rate now stands at 68.53%.
Over the past 67 months, CHRS's revenue has gone up $61,153,000.

The table below shows CHRS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 239.061 -193.493 -278.609
2022-06-30 276.14 -142.693 -230.487
2022-03-31 303.632 -92.844 -210.237
2021-12-31 326.551 -37.432 -287.1
2021-09-30 363.599 48.014 -231.667
2021-06-30 394.647 81.656 -165.206

CHRS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CHRS has a Quality Grade of B, ranking ahead of 82.07% of graded US stocks.
  • CHRS's asset turnover comes in at 0.513 -- ranking 78th of 682 Pharmaceutical Products stocks.
  • CPRX, XTNT, and VIVO are the stocks whose asset turnover ratios are most correlated with CHRS.

The table below shows CHRS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.513 0.886 -0.228
2021-03-31 0.572 0.913 -0.075
2020-12-31 0.664 0.921 0.250
2020-09-30 0.803 0.931 0.332
2020-06-30 0.995 0.936 0.477
2020-03-31 1.206 0.950 0.576

CHRS Price Target

For more insight on analysts targets of CHRS, see our CHRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.71 Average Broker Recommendation 1.57 (Moderate Buy)

Coherus BioSciences, Inc. (CHRS) Company Bio


Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.


CHRS Latest News Stream


Event/Time News Detail
Loading, please wait...

CHRS Latest Social Stream


Loading social stream, please wait...

View Full CHRS Social Stream

Latest CHRS News From Around the Web

Below are the latest news stories about COHERUS BIOSCIENCES INC that investors may wish to consider to help them evaluate CHRS as an investment opportunity.

Coherus Announces U.S. Launch of UDENYCA® Autoinjector

UDENYCA Autoinjector UDENYCA® Autoinjector is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – UDENYCA® AI is the only pegfilgrastim prefilled autoinjector product presentation available in the U.S. that can be administered either in-office or at-home – – UDENYCA® AI fulfills high unmet need by giving providers a new, innovative option that offers patients greater choice, independence and flexibility –

Yahoo | May 22, 2023

Coherus Prices Public Offering of Common Stock

REDWOOD CITY, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 1,764,705 shares of its common stock at the public o

Yahoo | May 16, 2023

Coherus Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less the underwriting discount. All of the shares of common stock to be sold in the offering will

Yahoo | May 15, 2023

News Flash: 8 Analysts Think Coherus BioSciences, Inc. (NASDAQ:CHRS) Earnings Are Under Threat

One thing we could say about the analysts on Coherus BioSciences, Inc. ( NASDAQ:CHRS ) - they aren't optimistic, having...

Yahoo | May 13, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with the biggest pre-market stock movers traders will want to keep in mind while trading on Tuesday!

William White on InvestorPlace | May 9, 2023

Read More 'CHRS' Stories Here

CHRS Price Returns

1-mo -43.56%
3-mo -41.64%
6-mo -40.55%
1-year -44.77%
3-year -78.50%
5-year -73.59%
YTD -47.98%
2022 -50.38%
2021 -8.17%
2020 -3.47%
2019 98.95%
2018 2.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!